Chemiluminescence Immunoassay Analyzers Market Size Worth USD 9.7 Billion in 2032 | Emergen Research
December 18, 2023 06:54 ET
|
Emergen Research
Vancouver, Dec. 18, 2023 (GLOBE NEWSWIRE) -- The global Chemiluminescence Immunoassay (CLIA) analyzers market size was USD 5.42 Billion in 2022 and is expected to register rapid revenue CAGR of 6.0%...
Crinetics to Highlight Broad Pipeline at ENDO 2023
June 09, 2023 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced upcoming presentations that will highlight the company’s pipeline at ENDO 2023, the...
Crinetics Pharmaceuticals Adds Board Member with Global Rare Disease Expertise with Appointment of Rogério Vivaldi Coelho, M.D., M.B.A.
January 05, 2022 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...
Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 25, 2021 16:01 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals to Unveil its Parathyroid Hormone Receptor Antagonist Program at the American Society for Bone and Mineral Research Annual Meeting
September 27, 2021 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
- Late-breaking Poster Presentation on Sunday, October 3, 2021 SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company...
Crinetics Pharmaceuticals Appoints Garlan Adams as General Counsel
June 16, 2021 08:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, June 16, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...
Crinetics Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 06, 2021 16:05 ET
|
Crinetics Pharmaceuticals, Inc.
Paltusotine Phase 3 PATHFNDR program in acromegaly initiated in 2Q 2021 Phase 1 data for CRN04894 and CRN04777 expected in mid-2021 SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- Crinetics...
Crinetics Pharmaceuticals Appoints Acromegaly Expert, Peter Trainer, Vice President of Clinical Endocrinology
November 16, 2020 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Hosting Key Opinion Leader Meeting Focusing on Oral Paltusotine for the Treatment of Acromegaly
November 13, 2020 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Provides New Data from Paltusotine and ACTH Antagonist Development Programs at European Congress of Endocrinology
September 04, 2020 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...